Articoli con mandati relativi all'accesso pubblico - Jean Jacques GrobUlteriori informazioni
Non disponibili pubblicamente: 3
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ...
The Lancet Oncology 19 (11), 1480-1492, 2018
Mandati: US National Institutes of Health
Melanoma
D Schadendorf, DE Fisher, C Garbe, JE Gershenwald, JJ Grob, A Halpern, ...
Nature reviews Disease primers 1 (1), 1-20, 2015
Mandati: US National Institutes of Health
Not all melanomas are created equal: a review and call for more research into nodular melanoma
C Dessinioti, AC Geller, DC Whiteman, C Garbe, JJ Grob, JW Kelly, ...
British Journal of Dermatology 185 (4), 700-710, 2021
Mandati: National Health and Medical Research Council, Australia
Disponibili pubblicamente: 48
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
Mandati: US National Institutes of Health
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
Mandati: National Institute for Health Research, UK
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
Mandati: Cancer Research UK, UK Medical Research Council
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
New England Journal of Medicine 375 (19), 1845-1855, 2016
Mandati: US National Institutes of Health
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ...
The lancet oncology 16 (5), 522-530, 2015
Mandati: US National Institutes of Health
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, ...
New England Journal of Medicine 386 (1), 24-34, 2022
Mandati: US National Institutes of Health
The role of BRAF V600 mutation in melanoma
PA Ascierto, JM Kirkwood, JJ Grob, E Simeone, AM Grimaldi, M Maio, ...
Journal of translational medicine 10, 1-9, 2012
Mandati: US National Institutes of Health
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 40 (2), 127-137, 2022
Mandati: US National Institutes of Health, National Institute for Health Research, UK
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ...
The Lancet Oncology 18 (7), 863-873, 2017
Mandati: US National Institutes of Health
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double …
GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ...
The Lancet Oncology 20 (8), 1083-1097, 2019
Mandati: US National Institutes of Health, National Health and Medical Research …
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort …
JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ...
The Lancet Oncology 19 (3), 310-322, 2018
Mandati: US National Institutes of Health, National Health and Medical Research …
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
M Maio, JJ Grob, S Aamdal, I Bondarenko, C Robert, L Thomas, C Garbe, ...
Journal of clinical oncology 33 (10), 1191-1196, 2015
Mandati: US National Institutes of Health
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study
SS Saini, C Bindslev-Jensen, M Maurer, JJ Grob, EB Baskan, MS Bradley, ...
Journal of Investigative Dermatology 135 (1), 67-75, 2015
Mandati: US National Institutes of Health
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2016
C Garbe, K Peris, A Hauschild, P Saiag, M Middleton, L Bastholt, JJ Grob, ...
European journal of cancer 63, 201-217, 2016
Mandati: Cancer Research UK
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of …
D Schadendorf, JD Wolchok, FS Hodi, V Chiarion-Sileni, R Gonzalez, ...
Journal of Clinical Oncology 35 (34), 3807-3814, 2017
Mandati: US National Institutes of Health, Cancer Research UK
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software